Europe gives generics merger the green flag


 

Two of the top five global generic medicines manufactures, Watson and Actavis, have been given the go-ahead to merge by the European Commission. Under the deal, Watson – which is predominantly active in the US – will acquire Actavis for €4.25 billion (£3.4 billion).

The combined company will become the third largest generics business in the world, after Israel’s Teva, and Sandoz, the generics arm of Swiss firm Novartis. According to Watson’s chief executive, Paul Bisaro, the aim of the acquisition is to strengthen the company’s position outside of the US. ‘In a single, commercially compelling transaction, we more than double Watson's international access and strengthen our commercial position in key established European markets as well as exciting emerging growth markets, including Central and Eastern Europe and Russia,’ he says.


Related Content

Megamerger brings Actavis into R&D race

25 February 2014 Business

news image

$25bn Forest Labs takeover will see generics giant take on patented products

Business roundup

28 July 2011 Business

news image

Industry news, August 2011

Most Read

Magnetic resonance taken to the limit

21 November 2014 Research

news image

Technique can read the spin of a single nucleus opening up a new way to investigate proteins and complex molecules

Boron and beryllium finally shake hands

24 November 2014 Research

news image

Never-before-seen bond observed between periodic table neighbours

Most Commented

US approves low acrylamide spud

25 November 2014 News and Analysis

news image

The first genetically modified potato that produces less acrylamide has been granted approval in the US

Nanostripe controversy in new twist

24 November 2014 Research

news image

Creator of striped nanoparticles insists questions over structures have already been answered and accuses critics of a 'perso...